- Home
- TPST vs CMMB Comparison
TPST vs CMMB Comparison
Compare TPST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TPST | CMMB |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 13.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TPST | CMMB |
|---|---|---|
| Price | $2.95 | $1.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $12.50 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 119.2K | 97.8K |
| Earning Date | 11-05-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $1.73 |
| 52 Week High | $13.65 | $9.84 |
Technical Indicators
Market Signals| Indicator | TPST | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 27.63 | 26.86 |
| Support Level | $2.87 | $1.73 |
| Resistance Level | $3.20 | $2.24 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | 0.24 | -0.04 |
| Stochastic Oscillator | 27.78 | 9.43 |
Price Performance
Historical ComparisonAbout TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.